http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee, K.,Park, C.,Moon, H.Y.,Ahn, E.,Park, H.E.,Ihm, S.H.,Seung, K.B.,Yoon, T.J.,Chang, K.,Lee, C.,Cheong, C.,Hong, K.S. Elsevier 2009 Current Applied Physics Vol.9 No.1
Magnetic ferrite nanoparticles (MNPs) are nano-sized magnets that distort the local magnetic field and alter the T<SUB>2</SUB> and T<SUB>2</SUB><SUP>*</SUP> of the water protons in the surrounding water molecules. This property renders MNPs a favorable negative MR contrast agent for biomedical applications. Silica coating and polyethylene glycolation confers additional stability and biocompatibility to the MNPs. Organic dyes incorporated into the silica shell enable the detection of MNP fluorescence by confocal laser scanning microscopy (CLSM). Mouse mesenchymal stem cells (mMSCs) in adult bone marrow can differentiate into cardiomyocytes. The mMSCs recruited in the region of myocardial infarction can express muscle-specific markers and increase the regional wall motion. Using MRI, we tracked the fate of MNP-labeled mMSCs injected into the infarcted myocardium. The mMSCs were effectively labeled with polyethylene-glycolated MNPs, as confirmed by CLSM. The MNP-labeled mMSCs were injected around and into the infarcted myocardium of C57/BL6 mice. Using MR, we successfully tracked the MNP-labeled mMSCs in the hearts of mice at 7d after inducing myocardial infarction. The localization of MNPs in the myocardium was validated by the in vivo and ex vivo MR images.
Cho, Jung Sun,Youn, Ho-Joong,Her, Sung-Ho,Park, Maen Won,Kim, Chan Joon,Park, Gyung-Min,Jeong, Myung Ho,Cho, Jae Yeong,Ahn, Youngkeun,Kim, Kye Hun,Park, Jong Chun,Seung, Ki Bae,Cho, Myeong Chan,Kim, C The Korean Academy of Medical Sciences 2015 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.30 No.7
<P>The prognostic value of the left ventricle ejection fraction (LVEF) after acute myocardial infarction (AMI) has been questioned even though it is an accurate marker of left ventricle (LV) systolic dysfunction. This study aimed to examine the prognostic impact of LVEF in patients with AMI with or without high-grade mitral regurgitation (MR). A total of 15,097 patients with AMI who received echocardiography were registered in the Korean Acute Myocardial Infarction Registry (KAMIR) between January 2005 and July 2011. Patients with low-grade MR (grades 0-2) and high-grade MR (grades 3-4) were divided into the following two sub-groups according to LVEF: LVEF ≤ 40% (n = 2,422 and 197, respectively) and LVEF > 40% (n = 12,252 and 226, respectively). The primary endpoints were major adverse cardiac events (MACE), cardiac death, and all-cause death during the first year after registration. Independent predictors of mortality in the multivariate analysis in AMI patients with low-grade MR were age ≥ 75 yr, Killip class ≥ III, N-terminal pro-B-type natriuretic peptide > 4,000 pg/mL, high-sensitivity C-reactive protein ≥ 2.59 mg/L, LVEF ≤ 40%, estimated glomerular filtration rate (eGFR), and percutaneous coronary intervention (PCI). However, PCI was an independent predictor in AMI patients with high-grade MR. No differences in primary endpoints between AMI patients with high-grade MR (grades 3-4) and EF ≤ 40% or EF > 40% were noted. MR is a predictor of a poor outcome regardless of ejection fraction. LVEF is an inadequate method to evaluate contractile function of the ischemic heart in the face of significant MR.</P>
Eigenvalue Ratio Test for the Number of Factors
Seung C. Ahn,Alex R. Horenstein 한국계량경제학회 2008 한국계량경제학회 학술대회 논문집 Vol.2008 No.2
This paper proposes two new estimators for determining the number of factors in approximate factor models. We exploit the well known fact that the r eigenvalues of the variance-covariance matrix of N response variables, where r is the number of comment factors in the variables, grow unboundedly as N increases. The criterion functions used for the two estimators are related to the ratio of two adjacent eigenvalues. An important advantage of the estimators is that they do not require the use of penalty functions. The estimators can be viewed as a reformulation of the well known scree test. We show that the estimators are consistent under the general conditions of Bai and Ng (2002). Our simulation results show that the estimators have good finite sample properties unless the signal-to-noise-ratio of each factor is too low. They perform much better than the Bai-Ng estimators do when either the number of the response variables analyzed or the number of time series observations, T, is small.
난소를 적출한 Rats에서 우울증, 불안장애, 식이섭취에 대한 석류추출물의 효과
안기훈 ( Ki Hoon Ahn ),이경욱 ( Kyong Wook Yi ),박현태 ( Hyun Tae Park ),신정호 ( Jung Ho Shin ),허준용 ( Jun Young Hur ),김영태 ( Young Tae Kim ),김선행 ( Sun Haeng Kim ),이규완 ( Kyu Wan Lee ),김승희 ( Seung Hee Kim ),배춘식 ( C 대한폐경학회 2010 대한폐경학회지 Vol.16 No.1
연구목적: 난소를 적출한 폐경모델 rats에서 석류추출물이 우울증, 불안장애, 식이섭취에 대해 효과가 있는지 알아보고자 하였다. 연구재료 및 방법: 79마리의 암컷 Sprague-Dawley rats을 이용하였다: A, 난소 적출하지 않고 약물 투여하지 않은 군; B, 가장수술 후 증류수투여군; C, D, E, F는 각각 난소적출 후 증류수, 10%, 20%, 40% 석류 투여군. 약물투여 4주째에 우울증 및 불안장애검사를 시행하였다. 24시간 먹이섭취량를 매일, 몸무게를 일주일에 한 번 측정하였다. 결과: 불안장애검사에서 10% 석류추출물이 % 폐쇄구역횟수를 유의하게 감소시켰다. 우울증검사에서는 석류추출물의 용량과 비례하여 immobility 시간의 감소를 보여주었다. 석류추출물의 투여가 난소 적출과 관련한 식이섭취의 증가 및 몸무게의 증가를 억제하지는 못하였다. 결론: 석류추출물은 난소를 적출한 폐경모델 rats에서 우울증 및 불안장애를 개선시켰다. Objectives: To determine whether or not pomegranate extract can affect depression, anxiety, and food intake in ovariectomized rats. Methods: Seventy-nine female Sprague-Dawley rats were divided into six groups: A, no operation and no drug intake; B, sham operation and distilled water; C, ovariectomy and distilled water; D, ovariectomy and 10% dilute pomegranate extract; E, ovariectomy and 20% dilute pomegranate extract; and F, ovariectomy and 40% dilute pomegranate extract. Beginning 2 days after surgery, drugs were administrated for 4 weeks. After that, the rats were subjected to the elevated plus maze (EPM) test and forced swim test (FST). Results: The 10% pomegranate extract had a lower % closed arm entry frequency in the EPM test. A pomegranate dose-dependent decrease in the duration of immobility duration in FST was shown. Pomegranate did not reverse ovariectomy-related hyperphagia and weight gain. Conclusion: Pomegranate extract improved depression and anxiety in a postmenopausal model with ovariectomized rats. (J Korean Soc Menopause 2010;16:39-45)
Lee, K.,Moon, H.Y.,Park, C.,Kim, O.R.,Ahn, E.,Lee, S.Y.,Park, H.E.,Ihm, S.H.,Seung, K.B.,Chang, K.,Yoon, T.J.,Lee, C.,Cheong, C.,Hong, K.S. Elsevier 2009 Current Applied Physics Vol.9 No.1
We have recently synthesized organic dye-incorporated silica-coated core-shell magnetic nanoparticles (MFSNs) that enable the detection of both fluorescence and magnetic properties in cells and tissues by using magnetic resonance imaging (MRI). Furthermore, polyethylene glycolation of the surface of these MFSNs would render them more stable and biocompatible, and thus allow their in vivo use as a circulating agent with a long half-life. Atherosclerotic vascular diseases are the leading cause of death worldwide. A noninvasive diagnostic imaging method is required to identify vulnerable plaques prior to the occurrence of a clinical event. Macrophages are the key cellular mediators in the pathogenesis of plaque inflammation and vulnerability. We evaluated whether the use of polyethylene glycolated (PEGylated) MFSNs could help in effectively detecting the macrophage activity in the aorta of apolipoprotein E (apoE)-deficient mice. PEGylated MFSNs (Fe, 30mg/kg) were injected via the tail vein in 1.2% cholesterol-fed 30-week-old apoE-deficient mice. After 24h, ex vivo MRI was carried out. The atheromas were then observed by confocal laser scanning microscopy (CLSM), and immunohistochemical staining targeted toward the macrophages was performed. Ex vivo MRI demonstrated robust enhancement of the atherosclerotic plaques along the aortic wall. CLSM images showed accumulation of PEGylated MFSNs in the atherosclerotic plaques, and histological examination revealed the localization of MFSNs in the macrophages present in the lesion. Therefore, PEGylated MFSNs could function as an effective multimodal imaging agent in the identification of macrophage activity in atherosclerotic plaques.
Korea Acute Myocardial Infarction Registry Investigators,Ji, M.S.,Jeong, M.H.,Ahn, Y.K.,Kim, S.H.,Kim, Y.J.,Chae, S.C.,Hong, T.J.,Seong, I.W.,Chae, J.K.,Kim, C.J.,Cho, M.C.,Rha, S.W.,Bae, J.H.,Seung, Elsevier/North-Holland Biomedical Press 2015 INTERNATIONAL JOURNAL OF CARDIOLOGY Vol.199 No.-
<P>Background: Despite common use of second-generation drug-eluting stents in treating patients with coronary artery disease, there is lack of data comparing these stents exclusively in patients with acute myocardial infarction (AMI), especially with metabolic syndrome (MetS), which is highly prevalent in AMI and potential to worsen clinical outcomes. The aim of this study was to compare clinical outcomes of everolimus-eluting stent (EES) and Resolute-zotarolimus-eluting stent (R-ZES) in AMI patients with MetS, in terms of stent-related and patient-related outcomes. Methods: A total of 3942 AMI patients in the KAMIR (Korea Acute Myocardial Infarction Registry) were grouped according to the presence of MetS and stent type: EES (N = 1582) and R-ZES (N = 255) in MetS (1837). Target lesion failure (TLF) and patient-oriented composite events (POCE) at 1 year were evaluated. Results: In MetS patients, TLF (3.7% vs. 2.7%, p = 0.592) and POCE (7.9% vs. 6.7%, p = 0.764) were similar between EES and R-ZES. Also in Non-MetS patients, TLF (3.9% vs. 3.1%, p = 0.307) and POCE (6.4% vs. 7.3%, p = 0.866) were similar between 2 groups. TLF was similar between MetS and Non-MetS patients (3.6% vs. 3.8%), while POCEs ( 7.7% vs. 6.6%) were higher in MetS. Propensity-score matching analysis showed similar results between stent groups in MetS and Non-MetS. In multivariate analysis, left ventricular ejection fraction and symptom-to-door time were independent predictors of TLF and POCE in MetS patients with AMI. Conclusions: In MetS patients with AMI, EES and R-ZES showed excellent performance and safety. However, patient-oriented composite events were relatively high, suggesting more efforts to improve them. (C) 2015 Published by Elsevier Ireland Ltd.</P>
KAMIR Investigators,Lee, K.H.,Jeong, M.H.,Kim, H.M.,Ahn, Y.,Kim, J.H.,Chae, S.C.,Kim, Y.J.,Hur, S.H.,Seong, I.W.,Hong, T.J.,Choi, D.H.,Cho, M.C.,Kim, C.J.,Seung, K.B.,Chung, W.S.,Jang, Y.S.,Rha, S.W. Elsevier Biomedical 2011 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY - Vol.58 No.16
Objectives: We investigated whether statin therapy could be beneficial in patients with acute myocardial infarction (AMI) who have baseline low-density lipoprotein cholesterol (LDL-C) levels below 70 mg/dl. Background: Intensive lipid-lowering therapy with a target LDL-C value <70 mg/dl is recommended in patients with very high cardiovascular risk. However, whether to use statin therapy in patients with baseline LDL-C levels below 70 mg/dl is controversial. Methods: We analyzed 1,054 patients with AMI who had baseline LDL-C levels below 70 mg/dl and survived at discharge from the Korean Acute MI Registry between November 2005 and December 2007. They were divided into 2 groups according to the prescribing of statins at discharge (statin group n = 607; nonstatin group n = 447). The primary endpoint was the composite of 1-year major adverse cardiac events, including death, recurrent MI, target vessel revascularization, and coronary artery bypass grafting. Results: Statin therapy significantly reduced the risk of the composite primary endpoint (adjusted hazard ratio [HR]: 0.56; 95% confidence interval [CI]: 0.34 to 0.89; p = 0.015). Statin therapy reduced the risk of cardiac death (HR: 0.47; 95% CI: 0.23 to 0.93; p = 0.031) and coronary revascularization (HR: 0.45, 95% CI: 0.24 to 0.85; p = 0.013). However, there were no differences in the risk of the composite of all-cause death, recurrent MI, and repeated percutaneous coronary intervention rate. Conclusions: Statin therapy in patients with AMI with LDL-C levels below 70 mg/dl was associated with improved clinical outcome.
other Korea Acute Myocardial Infarction Registry Investigators,Sim, D.S.,Jeong, M.H.,Ahn, Y.,Kim, Y.J.,Chae, S.C.,Hong, T.J.,Seong, I.W.,Chae, J.K.,Kim, C.J.,Cho, M.C.,Rha, S.W.,Bae, J.H.,Seung, K.B. Elsevier/North-Holland Biomedical Press 2016 INTERNATIONAL JOURNAL OF CARDIOLOGY Vol.221 No.-
<P>Background: Immediate invasive approach for non-ST-segment elevation myocardial infarction (NSTEMI) may permit treatment of the underlying plaque rupture as early as possible with subsequent reduction of death and myocardial infarction (MI). We sought to assess clinical impact of immediate percutaneous coronary intervention (PCI) for NSTEMI. Methods: A total of 6134 NSTEMI patients undergoing PCI from the Korea Acute Myocardial Infarction Registry were divided into group 1 (immediate PCI within 4 h, n = 1132) and group 2 (non-immediate PCI after 4 h, n = 5002). Propensity-matched 12-month clinical outcome was compared. Results: In all patients and propensity-matched cohort (n = 1131 in each group), group 1 had higher peak troponin level, higher rate of pre-PCI Thrombolysis In Myocardial Infarction (TIMI) grade 0 or 1, higher use of glycoprotein IIb/IIIa inhibitor, and lower use of unfractionated heparin and nitrates. In all patients, 12-month rates of MI and death/MI were higher in group 1. No differences were observed in 12-month death and major adverse cardiac events (MACE: composite of death, MI, target-vessel revascularization, and coronary artery bypass graft surgery). In propensity-matched cohort, no significant differences were observed in 12-month rates of death, MI, death/MI or MACE. However, group 1 had less major bleeding (0.8% vs. 3.0%, p = 0.024) and shorter hospital stay. Conclusions: Immediate PCI for patients with NSTEMI was associated with lower pre-PCI culprit vessel patency and not with improved 12-month clinical outcome. (C) 2016 Elsevier Ireland Ltd. All rights reserved.</P>
on behalf of KAMIR-NIH registry investigators,Park, K.H.,Jeong, M.H.,Ahn, Y.,Ahn, T.H.,Seung, K.B.,Oh, D.J.,Choi, D.J.,Kim, H.S.,Gwon, H.C.,Seong, I.W.,Hwang, K.K.,Chae, S.C.,Kim, K.B.,Kim, Y.J.,Cha, Elsevier/North-Holland Biomedical Press 2016 INTERNATIONAL JOURNAL OF CARDIOLOGY Vol.215 No.-
<P>Background: Although ticagrelor has been well-known to improve clinical outcomes in patients with acute myocardial infarction (AMI) without increased bleeding risk, its clinical impacts have not been well established in East Asian patients. Methods: Between November 2011 and June 2015, a total of 8010 patients (1377 patients were prescribed ticagrelor and 6633 patients clopidogrel) undergoing successful revascularization were analyzed from Korea Acute Myocardial Infarction Registry-National Institute of Health. The patients who discontinued or occurred in-hospital switching between two antiplatelet agents were excluded. Results: After propensity score matching (1377 pairs), no difference in the composite of cardiac death, MI, stroke, or target vessel revascularization at 6 months was observed between two groups (4.2% vs. 4.9%, p = 0.499). However, the incidences of in-hospital Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding were higher in ticagrelor than clopidogrel (2.6% vs. 1.2%, p = 0.008; 3.8% vs. 2.5%, p = 0.051). The in-hospital mortality was higher in patients with than those without TIMI major bleeding (11.3% vs. 0.9%, p < 0.001). In a subgroup analysis, a higher risk for in-hospital TIMI major bleeding with ticagrelor was observed in patients = 75 years or with body weight < 60 kg (odd ratio [OR] = 3.209; 95% confidence interval [CI] = 1.356-7.592) and in those received trans-femoral intervention (OR = 1.996; 95% CI = 1.061-3.754). Conclusions: Our study shows that ticagrelor did not reduce ischemic events yet, however, was associated with increased risk of bleeding complications compared with clopidogrel. Further large-scale, long-term, randomized trials should be required to assess the outcomes of ticagrelor for East Asian patients with AMI. (C) 2016 Elsevier Ireland Ltd. All rights reserved.</P>
other Korea Acute Myocardial Infarction Registry Investigators,Kim, H.K.,Jeong, M.H.,Ahn, Y.,Chae, S.C.,Kim, Y.J.,Hur, S.H.,Seong, I.W.,Hong, T.J.,Choi, D.H.,Cho, M.C.,Kim, C.J.,Seung, K.B.,Jang, Y.S. Japanese College of Cardiology 2017 Journal of cardiology Vol.69 No.1
<P>Conclusion: Despite improvements in door-to-balloon time, no parallel reductions in mortality rate and total ischemic time were observed. Total ischemic time was associated with mortality. The present study suggests that additional efforts are needed to shorten total ischemic time including patient and pre hospital systemic delay for better prognosis after primary PCI. (C) 2016 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.</P>